Aurisco(SH:605116)2022-04-29 16:00Financial Performance - The company's operating revenue for 2021 was RMB 803,362,668.37, an increase of 11.36% compared to RMB 721,440,229.88 in 2020[30]. - The net profit attributable to shareholders for 2021 was RMB 168,713,891.23, reflecting a growth of 7.31% from RMB 157,227,222.39 in the previous year[30]. - The company achieved a total revenue of 803,362,668.37 CNY in 2021, representing a year-on-year growth of 11.36%[80]. - The net profit attributable to shareholders was 16,871.39 CNY, an increase of 7.31% compared to the previous year[80]. - The company's total revenue for 2021 reached RMB 800,459,806.62, representing an increase of 11.52% compared to the previous year[88]. - The gross profit margin improved slightly to 49.12%, an increase of 1.82 percentage points year-on-year[88]. - The company reported a revenue increase of 15% year-over-year, reaching $500 million in Q2 2021[184]. - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting $550 million in revenue[184]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 1.30 per 10 shares, totaling RMB 52,130,000 based on a total share capital of 401,000,000 shares as of December 31, 2021[8]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2021 fiscal year[8]. - The company's total share capital as of the end of 2021 was 401 million shares[8]. Risks and Challenges - The company reported no significant risks that could materially affect its operations during the reporting period[10]. - The company faced challenges such as fluctuations in the RMB exchange rate and rising costs of raw materials and international shipping[38]. - The company experienced a foreign exchange loss of 7.4356 million yuan in 2021, impacting net profit due to fluctuations in the RMB/USD exchange rate[156]. - The company faces risks from changes in the international trade environment, with 95% of its revenue coming from overseas sales, which may be impacted by trade protectionism[154]. - Environmental protection and safety production risks are present due to the nature of the chemical synthesis processes involved in API production, requiring compliance with national standards[155]. Research and Development - Research and development expenses totaled 69.35 million yuan, a year-on-year increase of 46.45%, with 23 products currently in the R&D phase[48]. - The company has established six engineering technology innovation platforms focused on various drug development areas, enhancing its R&D capabilities[73]. - The company has a total of 6 R&D centers and employs 189 R&D personnel, accounting for 15.66% of total employees[118]. - R&D investment for the reporting period was CNY 69.35 million, representing 8.63% of revenue, with a year-on-year growth of 46.45%[125]. - The company is developing several new drug projects, including a COVID-19 treatment and a GLP-1 receptor agonist for diabetes management, currently in various stages of development[119]. - The company has received multiple GMP certifications for its raw materials, including Abiraterone Acetate and Pregnenolone, enhancing its production capabilities[121]. Market and Sales - Sales of the core product, Dydrogesterone, continued to grow, with the company being one of the few globally capable of commercial production of Dydrogesterone raw materials[40]. - Domestic sales grew by 42.50% year-on-year, with collaborations established with leading domestic pharmaceutical companies[44]. - The company is actively expanding its domestic market presence, collaborating with leading domestic enterprises for multi-product cooperation[78]. - The marketing strategy focuses on customer-centric approaches, expanding market share in Europe, America, and Asia while collaborating with domestic formulation companies[150]. Investments and Acquisitions - The company invested approximately 500 million yuan in the construction of a new facility in Yangzhou, which includes multiple production workshops and a pilot testing center[45]. - The company acquired a 51.03% stake in Guangdong Zhuotai Pharmaceutical for 51 million yuan, focusing on synthetic biology research and applications[49]. - The company invested RMB 15 million to acquire a 10% stake in Yuandao Pharmaceutical (Suzhou) Co., Ltd., marking its entry into the innovative drug sector[55]. - The company completed an investment of RMB 51.03 million for a 51.03% stake in Guangdong Zhuotai Pharmaceutical Co., Ltd. during the reporting period[136]. Management and Governance - The total pre-tax remuneration received by directors and senior management during the reporting period amounts to 1,233.31 million yuan[180]. - The company has appointed directors and senior management personnel with extensive experience in various industries, including pharmaceuticals and international trade[188]. - The company’s board of directors has been consistent in its governance, with meetings held regularly to review financial reports and strategic decisions[191]. - The company has not reported any changes in shareholding for the directors and senior management during the reporting period[180]. Operational Efficiency - The company aims to reduce operational costs by 5% through process optimization initiatives[182]. - The company has reduced operational costs by 5%, resulting in improved profit margins[184]. - The company is focusing on technological innovation and product development to enhance competitiveness in the raw material drug industry[141]. Future Outlook - The company provided guidance for the next fiscal year, expecting revenue to grow by 10% to $1.65 billion[182]. - The company plans to establish a research and production platform for small molecule drugs, peptides, RNA drugs, and innovative drugs, expanding from APIs to formulations[145]. - The company intends to build new production capacity, including a project for 308 tons of specialty APIs and a production line for 200 million oncology formulations, expected to be completed by December 2024[149].